Anasuya Hazra
Overview
Explore the profile of Anasuya Hazra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Russu A, Hazra A, Tian H, Haddish-Berhane N, Perez Ruixo J, Boulton M
Adv Ther
. 2025 Feb;
PMID: 40016438
Introduction: Use of niraparib and abiraterone acetate (AA; abiraterone prodrug) in patients with metastatic castration-resistant prostate cancer (mCRPC) targets two oncogenic drivers: homologous recombination repair (HRR) gene alterations and the...
2.
Bumma N, Richter J, Jagannath S, Lee H, Hoffman J, Suvannasankha A, et al.
J Clin Oncol
. 2024 Jun;
42(22):2702-2712.
PMID: 38879802
Purpose: We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen × CD3 bispecific antibody...
3.
Yu A, Hazra A, Jiao J, Hellemans P, Mitselos A, Tian H, et al.
Clin Pharmacokinet
. 2024 Mar;
63(4):511-527.
PMID: 38436924
Background And Objective: The combination of niraparib and abiraterone acetate (AA) plus prednisone is under investigation for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive...
4.
Chang C, Vong C, Wang X, Hazra A, Diehl A, Nicholas T, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Feb;
13(4):599-611.
PMID: 38298058
These analyses characterized tofacitinib pharmacokinetics (PKs) in children and adolescents with juvenile idiopathic arthritis (JIA). Data were pooled from phase I (NCT01513902), phase III (NCT02592434), and open-label, long-term extension (NCT01500551)...
5.
Davis J, Bravo Padros M, Conrado D, Ganguly S, Guan X, Hassan H, et al.
Clin Pharmacol Ther
. 2023 Dec;
115(3):422-439.
PMID: 38093583
Subcutaneous (s.c.) administration of monoclonal antibodies (mAbs) can reduce treatment burden for patients and healthcare systems compared with intravenous (i.v.) infusion through shorter administration times, made possible by convenient, patient-centric...
6.
Mitra A, Lee J, Steinbach D, Hazra A, Krishna R
J Pharmacokinet Pharmacodyn
. 2023 Nov;
50(6):475-493.
PMID: 37925369
There are many challenges with rare diseases drug development and rare oncology indications are not different. To understand the regulatory landscape as it relates to application of clinical pharmacology principles...
7.
Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo J, et al.
Cancer Chemother Pharmacol
. 2022 Mar;
89(4):499-514.
PMID: 35298698
Purpose: To assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of cetrelimab (JNJ-63723283), a monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor, in patients with advanced/refractory solid tumors in the...
8.
Yu A, Erba M, Hazra A
Clin Pharmacol Drug Dev
. 2021 Jul;
10(11):1375-1384.
PMID: 34273257
Patients may have difficulty swallowing a whole daily dose of 240 mg (4 × 60-mg tablets) of apalutamide. One of the unique properties of apalutamide tablets is easy disintegration and...
9.
Ayyar V, Jaiprasart P, Geist B, Huang Devine Z, Case M, Hazra A, et al.
Br J Pharmacol
. 2021 May;
178(19):3943-3958.
PMID: 34008170
Background And Purpose: Antigen-binding fragment (F ) reversal agents were developed to reverse, in bleeding emergency, the long-acting anticoagulant effect of JNJ-64179375 (JNJ-9375), a monoclonal antibody that binds exosite-1 on...
10.
Saad F, Chi K, Shore N, Graff J, Posadas E, Lattouf J, et al.
Cancer Chemother Pharmacol
. 2021 Mar;
88(1):25-37.
PMID: 33754187
Purpose: To assess the safety and pharmacokinetics and determine the recommended phase 2 dose (RP2D) of niraparib with apalutamide or abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant...